Workflow
医药生物行业创新药周报（20241014-20241020）
Guoxin Securities Co., Ltd·2024-10-23 10:03

Investment Rating - The report gives a "Positive" investment rating for the pharmaceutical and biotechnology industry [1]. Core Viewpoints - The report highlights significant advancements in innovative drugs, with several new approvals and applications in the market, indicating a robust pipeline and growth potential in the sector [1][2]. - The approval of HER2-targeted ADC drug ENHERTU for specific NSCLC patients is a notable development, filling a gap in treatment options for this patient population [2]. - The report emphasizes the strong performance of certain stocks in the innovative drug sector, with notable gains in both A-share and Hong Kong markets [1]. Summary by Sections Market Review - The A-share innovative drug sector saw top performers such as Kaiyin Technology (up 12.75%), Nuocheng Jianhua-U (up 12.57%), and Sanofi Guojian (up 9.31%) last week. Conversely, Junshi Biosciences-U, Fosun Pharma, and Shouyao Holdings-U experienced declines [1]. - In the Hong Kong market, notable gainers included Laika Pharmaceuticals-B (up 42.26%), Beihai Kangcheng-B (up 25.00%), and Zai Lab (up 14.38%) [1]. Domestic R&D Progress - Four innovative drugs/improved new drugs were approved for market entry, and 15 innovative drugs/improved new drugs submitted for approval last week [1]. - The report mentions the approval of ENHERTU for treating advanced NSCLC patients with HER2 mutations, based on positive results from clinical trials [2]. Global R&D Progress - Global developments include the resubmission of a BLA for a combination therapy involving carrelizumab for liver cancer, which has been accepted by the FDA [1]. - GSK's first-in-class oral antibiotic targeting topoisomerase II has also received priority review from the FDA for treating uncomplicated urinary tract infections [1]. Corporate Collaborations - Baiyu Pharmaceutical signed an exclusive licensing agreement with Novartis for an anti-tumor drug, receiving an upfront payment of $70 million and potential milestone payments up to $1.1 billion [1].